NYSE:ASH
NYSE:ASHChemicals

How Investors Are Reacting To Ashland (ASH) Goodwill Impairment and Lowered Full-Year Outlook

Ashland Inc. recently reported third-quarter results reflecting a sharp drop in sales to US$463 million and a net loss of US$742 million, mainly driven by a US$706 million non-cash goodwill impairment charge. This significant write-down and lower sales prompted Ashland to update its full-year guidance toward the lower end of its projected sales range, highlighting ongoing headwinds and elevated uncertainty in its core markets. We'll examine how the substantial goodwill impairment highlights...
NYSE:MGM
NYSE:MGMHospitality

Is the Revenue-Profit Gap in MGM Resorts International’s Q2 Results Reshaping the MGM Investment Story?

MGM Resorts International recently reported its second quarter 2025 results, showing year-over-year revenue growth to US$4.40 billion, but net income fell to US$48.95 million from US$187.07 million over the same period last year. Despite stronger revenues, the sizable drop in net income highlights pressures on profitability that could influence perspectives on the company’s future performance. We’ll examine how the contrast between higher revenue and reduced profit shapes MGM’s current...
NasdaqGS:PTCT
NasdaqGS:PTCTBiotechs

Why PTC Therapeutics (PTCT) Is Up 8.2% After FDA Approves SEPHIENCE for Broad PKU Treatment

On July 28, 2025, PTC Therapeutics announced that the U.S. Food and Drug Administration approved SEPHIENCE™ (sepiapterin) for the treatment of phenylketonuria (PKU) in patients as young as one month old, with broad labeling across all PKU subtypes and based on significant clinical evidence from the Phase 3 APHENITY trial and its long-term extension. This regulatory milestone allows PTC Therapeutics to address a substantial unmet need in PKU treatment and expands its market presence through...
NYSE:ROL
NYSE:ROLCommercial Services

Rollins’ (ROL) Steady Capital Return: Confidence in the Model or a Sign to Diversify?

Rollins, Inc. recently reported its second-quarter earnings, showing net income of US$141.49 million and basic earnings per share of US$0.29 from continuing operations, both higher than the prior year. The completion of its multi-year share buyback program and the reaffirmation of its regular dividend highlight Rollins' ongoing efforts to return capital to shareholders. We'll explore how Rollins' improved quarterly earnings may influence its investment narrative and future performance...
NYSE:VIK
NYSE:VIKHospitality

Strong Q1 Revenue Growth and Analyst Optimism Might Change the Case for Investing in Viking Holdings (VIK)

In late July 2025, Bank of America reiterated a positive outlook on Viking Holdings, citing continued strength in cruise demand and recently reported financial results showing a 24.9% year-over-year rise in first quarter revenue despite a net loss. This event highlights both growing investor optimism toward the cruise sector and Viking's ability to generate revenue growth even amidst industry headwinds. We'll examine how this renewed analyst confidence, driven by Viking's substantial revenue...